Irhythm Technologies Inc. (IRTC)
Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?
iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevated.
iRhythm: The Algorithmic Margin Inflection Changes The Story
iRhythm Technologies is evolving from a cardiac patch producer to a comprehensive cardiac monitoring platform, leveraging software and workflow integration for a competitive advantage. Q2 2026 marked a financial inflection: 20.1% revenue growth, 72.8% gross margin, and adjusted EBITDA margin expansion to 19.3%, with raised full-year guidance and record free cash flow. The ZEUS platform's FDA clearance enables significant margin leverage, reducing clinician review time by 50% and targeting $100 million in cost savings over five years.
iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform
IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.
Here's Why iRhythm Holdings, Inc. (IRTC) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised
IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.
iRhythm Holdings, Inc. (IRTC) Q2 2026 Earnings Call Transcript
iRhythm Holdings, Inc. (IRTC) Q2 2026 Earnings Call Transcript
iRhythm Holdings, Inc. (IRTC) Tops Q2 Earnings and Revenue Estimates
iRhythm Holdings, Inc. (IRTC) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.32 per share a year ago.
iRhythm Technologies Q2 Earnings Call Highlights
iRhythm Technologies NASDAQ: IRTC reported second-quarter revenue growth of 20.1% and raised its full-year outlook, while announcing an agreement to acquire VitalConnect to broaden its cardiac monitoring portfolio and enter additional patient-monitoring markets.
iRhythm Technologies Touts Medicare Win, Zio Growth and AI-Driven Margin Gains
iRhythm Technologies NASDAQ: IRTC executives said the company is seeing continued business momentum after a favorable Medicare coverage update, a stronger-than-expected first quarter and progress on several product and margin initiatives.
iRhythm Holdings, Inc. (IRTC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
iRhythm Holdings, Inc. (IRTC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Wall Street Analysts Predict a 57.21% Upside in IRHYTHM HLDGS (IRTC): Here's What You Should Know
The consensus price target hints at a 57.2% upside potential for IRHYTHM HLDGS (IRTC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why iRhythm Holdings, Inc. (IRTC) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
